Consistently, we reversed this outcome by repetitively injecting FDA-approved monoclonal anti-PCSK9 antibodies into the peritoneum of an AD mouse model, resulting in substantially decreased cerebral Aβ concentrations and improved hippocampus-dependent learning behaviour compared to control-treated mice [132]. This evidence concerns the gene PCSK9 and Alzheimer disease.